Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.
January 17, 2020 — Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, does not comment on pending litigations per its corporate policy. However, Bracco is pleased to announce today that the lawsuit filed by Chuck and Gena Norris, in which Mrs. Norris alleged injury from Bracco’s magnetic resonance (MR) contrast agent MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, has been voluntarily dismissed by the Norris couple. The case is now closed. The decision to dismiss the lawsuit was entirely that of Chuck and Gena Norris and their attorneys. No settlement payment was made and each party paid their own costs.
For more information: https://imaging.bracco.com/us-en
Related Content of MRI Gadolinium Safety Concerns
VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D.
VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D.
Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety
Recent Developments in Contrast Media
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
European Medicines Agency Issues Update on Gadolinium Contrast Agents
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
FDA: No Harm in MRI Gadolinium Retention in the Brain
VIDEO: MRI Gadolinium Contrast Retention in the Brain
Gadolinium May Remain in Brain After Contrast MRI
April 13, 2024 
